Chicago Partners Investment Group LLC Increases Stock Position in Evolent Health, Inc. (NYSE:EVH)

Chicago Partners Investment Group LLC boosted its position in shares of Evolent Health, Inc. (NYSE:EVH) by 50.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,643 shares of the technology company’s stock after purchasing an additional 4,547 shares during the period. Chicago Partners Investment Group LLC’s holdings in Evolent Health were worth $153,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Evolent Health during the fourth quarter valued at about $31,000. Covestor Ltd boosted its holdings in Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC grew its stake in Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after purchasing an additional 1,556 shares in the last quarter. KBC Group NV increased its holdings in Evolent Health by 124.6% during the 4th quarter. KBC Group NV now owns 6,741 shares of the technology company’s stock worth $76,000 after purchasing an additional 3,739 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC acquired a new position in shares of Evolent Health in the 4th quarter valued at approximately $134,000.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on EVH shares. JPMorgan Chase & Co. dropped their price target on shares of Evolent Health from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Barclays dropped their target price on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Stephens reduced their price target on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 21st. Needham & Company LLC started coverage on Evolent Health in a report on Friday, January 10th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Truist Financial reduced their target price on Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $18.38.

Evolent Health Stock Performance

Shares of EVH opened at $10.35 on Thursday. The firm has a fifty day moving average of $11.17 and a 200-day moving average of $19.84. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -11.38 and a beta of 1.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health, Inc. has a 1 year low of $9.74 and a 1 year high of $35.00.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The firm had revenue of $621.40 million for the quarter, compared to analyst estimates of $625.58 million. During the same period in the previous year, the firm earned $0.19 earnings per share. As a group, equities analysts anticipate that Evolent Health, Inc. will post 0.24 earnings per share for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.